#SPRB

5 months ago

🚀 Exciting times for #SPRB! Trading at $172.5 with bullish momentum, but watch that high RSI of 81.1! 📈 Consider a long position at $170, targeting $180 & $190. Stop loss at $160. Biotech's volatility is real, so stay sharp! 🔍 #FeetrAI #StockMarket #Biotech

0 0 0 0

5 months ago

🚀 Exciting times for #SPRB! Trading at $172.89, it's riding a bullish wave with FDA breakthrough buzz. RSI over 80 signals overbought, but momentum is strong. Targeting $185 & $200, with a stop at $160. Stay alert for news—biotech's a wild ride! 📈 #FeetrAI #StockWatch

0 0 0 0

5 months ago

🚀 Exciting times for #SPRB! With RSI over 80 and a positive MACD, momentum is strong, but caution is key. Low volume hints at liquidity issues, and $188.25 resistance looms. Consider a short at $171.5, targeting $160/$150 with a stop at $180. Stay alert for news! 📈 #FeetrAI

0 0 0 0

5 months ago

🚀 Exciting times for #SPRB! With a price at $171.08, it's riding a wave of bullish momentum, but watch out for overbought signals. Speculative play due to its small-cap biotech status and FDA breakthrough. Consider a long position at $168, targeting $180-$190. 📈 #FeetrAI

0 0 0 0

5 months ago

🚀 Exciting times for #SPRB! With FDA approval boosting sentiment and trading volume, this biotech gem shows strong bullish momentum. Consider a long position at $165, aiming for $180 & $195 targets. Stay cautious with a stop loss at $155. Dive in, but stay sharp! 📈 #Biotech #Stocks

0 0 0 0

5 months ago

🚀 Exciting times for #SPRB! With a price surge to $165.15 and strong bullish momentum, this small-cap is catching eyes. RSI is overbought at 79.58, signaling potential gains. Consider entering at $162.50, targeting $170-$175. Stay sharp, market's volatile! 📈 #Stocks #FeetrAI

0 0 0 0

5 months ago

🚀 Exciting times for #SPRB! With FDA breakthrough status, this small-cap biotech is on a bullish run. RSI over 70 & positive MACD hint at more gains, but watch out for market volatility. Consider entry at $158, targeting $170 & $180. Stay sharp, traders! 📈 #FeetrAI

0 0 0 0

5 months ago

🚀 Exciting times for #SPRB! With FDA breakthrough status, it's surging at $159.01! 📈 Strong bullish momentum but watch out for volatility. Consider entering at $155, targeting $175 & $190. Stop loss at $145. Stay sharp, biotech's a wild ride! #FeetrAI #BiotechBoom

0 0 0 0

5 months ago

🚀 Exciting times for #SPRB! Positive trial results are fueling bullish momentum, with the stock soaring above key moving averages. Consider a LONG position at $160, targeting $175 & $190. High-risk, high-reward play—stay sharp! 📈 #Biotech #InvestSmart

0 0 0 0

5 months ago

🚀 Exciting times for #SPRB! Trading at $161, it's riding a bullish wave with FDA breakthrough buzz. RSI over 70 signals overbought, but strong MACD backs the momentum. Consider going LONG at $160, aiming for $175 & $190 targets. Stay sharp—volatility is high! 📈 #FeetrAI

0 0 0 0

Spruce Biosciences Announces $50.0 Million Private Placement Financing Spruce Biosciences (Nasdaq: SPRB) entered a definitive securities purchase agreement for a private placement expected to raise approximately $50.0 million gross before expenses. The financing covers sale of ~502,181 common shares at $68.00 per share and issuance of pre-funded warrants to buy up to 233,144 shares at $67.99, exercisable for five years.Proceeds are intended to advance tralesinidase alfa (TA-ERT) toward a BLA submission in Q1 2026 and a potential U.S. commercial launch in late 2026. The private placement is expected to close on or about October 9, 2025, subject to customary conditions, with placement agents and a capital markets advisor named.

5 months ago

#SPRB Spruce Biosciences Announces $50.0 Million Private Placement Financing

www.stocktitan.net/news/SPRB/spruce-bioscie...

0 0 0 0

5 months ago

Just In: ( NASDAQ: #SPRB ) US Companies Moving the Markets, Evening edition <br>Tue, Oct 07, 2025 as of 4:00 pm ET

0 0 0 0

5 months ago

JUST IN: ( NASDAQ: #SPRB ) Biotech Breakthroughs and AI War Chests Drive Late-Day Surge

0 0 0 0

5 months ago

NEWS: ( NASDAQ: #SPRB ) Spruce Biosciences Inc. (NASDAQ: SPRB) Rises Sharply in 10/6 Early Trading Session

0 0 0 0

5 months ago

News; ( NASDAQ: #SPRB ) US Companies Moving the Markets, Morning edition <br>Tue, Oct 07, 2025 as of 10.00 am ET

0 0 0 0

@wallstreetpulse.bsky.social

5 months ago

News; ( NASDAQ: #SPRB ) Morning Market Brief: Quiet Rockets and Loud Leaders

0 0 0 0

5 months ago

$SPRB STOCK ANALYSIS - SPRB Spruce Biosciences YouTube video by Hisseseven

youtu.be/kVyDcDM4ud4?... #sprb

0 0 0 0

PRISM MarketView

@prismmarketview.bsky.social

5 months ago

PRISM Morning Movers:
Top Gainers:
#Galecto, Inc. ( #GLTO) - up 726%
#C3is Inc. ( #CISS) - up 55%
#SpruceBiosciences, Inc. ( #SPRB) - up 41%
#LexeoTherapeutics, Inc. ( #LXEO) - up 32%
Top Decliners:
#SocietyPass Incorporated ( #SOPA) - down 25%
#SANUWAVE Health, Inc. ( #SNWV) - down 18%

0 0 0 0

5 months ago

BREAKING NEWS: ( NASDAQ: #SPRB ) Breakthroughs, Big Bets, and Billion-Dollar Builds

0 0 0 0

Spruce Biosciences Receives U.S. FDA Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB) Spruce Biosciences (NASDAQ: SPRB) announced the U.S. FDA has granted Breakthrough Therapy Designation to tralesinidase alfa enzyme replacement therapy (TA-ERT) for Sanfilippo Syndrome Type B (MPS IIIB).FDA confirmed CSF HS‑NRE as a surrogate biomarker reasonably likely to predict clinical benefit and usable for accelerated approval. Integrated long‑term clinical data reportedly show normalization of CSF HS‑NRE and stabilization of cortical grey matter volume and cognitive function in children with MPS IIIB. Spruce said a Biologics License Application (BLA) submission for TA‑ERT remains on track for Q1 2026.

5 months ago

#SPRB Spruce Biosciences Receives U.S. FDA Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB)

www.stocktitan.net/news/SPRB/spruce-bioscie...

0 0 0 0

Major Rare Disease Breakthrough: Spruce Bio Secures Promising Treatment for Fatal Childhood Disease First potential treatment for Sanfilippo Syndrome Type B shows promising 5-year data. FDA fast-track drug targets rare childhood disease. See development timeline.

11 months ago

#SPRB Spruce Biosciences Announces New Corporate Strategy and Acquisition of Tralesinidase Alfa for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)

www.stocktitan.net/news/SPRB/spruce-bioscie...

0 0 0 0